5:57 PM
 | 
Sep 20, 2013
 |  BC Extra  |  Top Story

Prosensa plummets on DMD data

Prosensa Holding N.V. (NASDAQ:RNA) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said drisapersen ( PRO051) missed the primary endpoint in a Phase III trial to treat Duchenne muscular dystrophy (DMD), sending Prosensa's shares down $16.86 (70%) to $7.14 on Friday. The partners said that in the DEMAND 3 (DMD114044) trial, once-weekly subcutaneous 6 mg/kg drisapersen led to a mean reduction of about...

Read the full 291 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >